Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Research Excellence Framework (REF) is the UK’s system for assessing the quality of research in UK higher education institutions. It first took place in 2014. The next exercise will be conducted in 2021.

Preparations are underway for REF2021.  Paul Harrison from Psychiatry has been chosen to lead our submission for Unit of Assessment 4 Psychology Psychiatry and Neuroscience.  Paul successfully led our submission for REF2014 when Oxford was ranked top in the UK on the overall quality of our submission, and had the highest proportion of world leading research. We scored 100% for the quality of our research and training environment. 95% of our submission was rated as world leading or internationally excellent.  That was an outstanding performance.

Some of our Neuroscience research is returned under Unit of Assessment 5 Biological Sciences which was also highly commended under REF2014. For REF2021 Unit of Assessment 5 will be led by Francis Barr from the Department of Biochemistry. 

Research Impact plays an important part of our assessment.  The Neuroscience, Psychology and Psychiatry Impact Team is currently being chaired by Charles Vincent while David Clark is on sabbatical.

Similar stories

Kia Nobre steps down as Head of Department

Matthew Rushworth replaces Kia Nobre as interim Head of the Department of Experimental Psychology

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Experimental Medicine and Industry Partnership

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.